Wilex AG has elected to receive a final cash payment from Prometheus Laboratories Inc (Nestle SA) in connection with the out-licensing in 2011 of its cancer product Rencarex (girentuximab). The product is in a Phase 3 registration trial.
Oxford BioMedica Plc is about to extend its cash runway thanks to a decision by its pharmaceutical partner, Sanofi SA, to in-license two gene-based ophthalmology products. The decision enabled the company to ask its institutional investors for more support. And they have responded with a commitment to provide £11 million for additional working capital.
The US Food and Drug Administration has approved the first DNA test to help healthcare professionals evaluate the progress of anti-viral treatment in solid organ transplant patients undergoing cytomegalovirus (CMV) antiviral therapy.
Venture-capital backed Prosonix Ltd has entered into a research agreement with Imperial College London to accelerate development of technology that is intended to improve the delivery of respiratory medicines. Financial terms weren’t disclosed.
The US Food and Drug Administration has approved the first over-the-counter, self-administered test to detect the presence of antibodies to the human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2).
GlaxoSmithKline Plc said that it will pay $3 billion to settle several criminal and civil cases brought against it by the US government, several states and the District of Columbia relating to past sales and marketing practices, including sales of Avandia.
The steep rise in pharmaceutical prices over recent decades has finally come to a halt and prices are now showing signs of declining at an accelerating pace. As a result, Big Pharma is asking European policy makers to do something about it.
Bristol-Myers Squibb Company and AstraZeneca Plc are set to strengthen their diabetes franchise through a staged deal in which BMS will acquire Amylin Pharmaceuticals Inc and thereafter exploit Amylin’s portfolio with AstraZeneca
GlaxoSmithKline Plc has again extended its $13 per share cash offer for Human Genome Sciences Inc- this time to a date after management will have completed a review of other strategic options. GSK’s offer to shareholders is now set to expire on 20 July.
Oxford BioMedica Plc has announced plans to raise up to £16 million in a combined private share placement and open offer. The proceeds will be used to continue development of its gene therapy technology, particularly in the area of ophthalmology.